Astellas Pharma

ALPMY

16.8435.14% ( +0.823 )

Delay Trading: Nov 5, 10:16:00 (EDT)

Current ValuationThe current P/E ratio is 11.84, within the reasonable range, cheaper than 79.31% of the time in the past 1 years, and the industry ranks 17/257, the industry Median -1.07.

11.84xP/E

Stock price$16.02Earnings per share$1.35

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

03876114152

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
NVOUSNovo Nordisk AS	10.70x	4.69%	$186.17B
BMYUSBristol Myers Squibb	14.20x	52.04%	$131.21B
SNYUSSanofi	11.85x	29.05%	$56.87B
ZTSUSZoetis	13.98x	4.22%	$36.86B
ALPMYUSAstellas Pharma	11.84x	--	$28.72B
SGIOYUSShionogi	10.72x	--	$16.29B
EWTXUSEdgewise Therapeutics	4.04x	187.50%	$4.08B
SNPHYUSSanten Pharmaceutical	14.89x	--	$3.68B
SUPNUSSupernus	7.40x	126.83%	$3.33B
HYPMYUSHypera S.A.	7.96x	--	$2.75B
PBHUSPrestige Brands	14.67x	8.89%	$2.52B
HRMYUSHarmony Biosciences	11.22x	44.42%	$2.00B
INVAUSInnoviva	7.94x	32.30%	$1.54B
GTBIFUSGreen Thumb Industries Inc.	11.99x	--	$1.52B
OMERUSOmeros	10.54x	1,913.34%	$1.32B
ZVRAUSZevra Therapeutics	8.85x	16.93%	$663.32M
APMDUSApnimed	3.72x	114.94%	$609.29M
CRMDUSCormedix	2.37x	75.82%	$441.16M
ORMPUSOramed Pharma	0.99x	198.00%	$171.80M
OGIUSOrganigram	2.09x	509.06%	$130.28M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.